Perspectivas del mercado y visión del analista:
El cáncer de estómago, también conocido como cáncer gástrico, se debe al crecimiento anormal y fuera de control de las células malignas en el estómago. Los factores de riesgo que conducen al riesgo de cáncer de estómago incluyen la edad y la alimentación. La indigestión, el malestar estomacal, la pérdida de apetito, la acidez de estómago y la pérdida de peso son síntomas del cáncer de estómago. Se emplean diferentes enfoques para tratar el cáncer de estómago, como la quimioterapia, la radioterapia y la inmunoterapia. El crecimiento del mercado del cáncer de estómago está influenciado por factores como la creciente incidencia del cáncer de estómago, los avances en el tratamiento, incluida la quimioterapia, la cirugía y las terapias dirigidas, y los esfuerzos continuos de investigación y desarrollo para mejorar los resultados de los pacientes. Con el creciente énfasis en el diagnóstico temprano y los enfoques de tratamiento personalizados, se espera que el mercado del tratamiento del cáncer de estómago continúe expandiéndose en el futuro.
Impulsores de crecimiento:
Las empresas del mercado de la salud están llevando a cabo diversas actividades de investigación y desarrollo para introducir Tratamientos innovadores para el cáncer gástrico. Además, los tratamientos se están evaluando en ensayos clínicos y también se desarrollan e investigan constantemente nuevos enfoques a través de ensayos clínicos. A continuación se mencionan algunos de los productos en proceso:
En diciembre de 2022, Zhejiang Doer Biologics Co., Ltd celebró un acuerdo de colaboración en ensayos clínicos con Merck & Co., Inc., para evaluar el anti-Claudin18 de Doer Bio. 2 DR30303, en combinación con la terapia anti-PD-1 de Merck, KEYTRUDA (pembrolizumab), en pacientes con cáncer gástrico o de la unión gastroesofágica. Según los términos del acuerdo, Doer Bio llevó a cabo un estudio experimental basado en un protocolo finalizado y acordado mutuamente para investigar la seguridad y eficacia de DR30303 en combinación con KEYTRUDA en la unión gástrica o gastroesofágica localmente avanzada irresecable o metastásica con Claudin18.2 positivo. pacientes con cáncer. En noviembre de 2022, Triumvira Immunologics proclamó datos preclínicos para sus terapias en investigación con células TAC-T CLDN18.2-TAC T y GUCY2C-TAC T, así como datos sobre productos TAC-T específicos de HER2. La compañía mostró los datos actualizados sobre su nuevo candidato de células T acoplador de antígeno de células T (TAC) dirigido a Claudin 18.2 para el tratamiento del cáncer gástrico. En septiembre de 2022, Nuvectis Pharma, Inc. anunció datos positivos para NXP800 en un modelo de xenoinjerto preclínico de ARID1a- Carcinoma gástrico mutado. Los volúmenes de los tumores se midieron durante 28 días después de que los ratones de cada grupo fueran tratados con un vehículo o con un tratamiento con NXP800. La regresión del tumor y una inhibición significativa del crecimiento del tumor fueron los resultados del tratamiento con NX800 en comparación con el control. Por lo tanto, el creciente número de ensayos clínicos ayuda a aumentar la disponibilidad del tratamiento del cáncer gástrico en todo el mundo, lo que, a su vez, impacta positivamente el crecimiento del cáncer de estómago. mercado.
Perspectivas estratégicas
Segmentación y alcance del informe:
El mercado del cáncer de estómago está segmentado según el tipo, tratamiento, vía de administración, canal de distribución y geografía. Según el tipo, el mercado del cáncer de estómago se clasifica en adenocarcinomas, tumores del estroma gastrointestinal, tumores neuroendocrinos, linfoma y otros. Según el tratamiento, el mercado del cáncer de estómago se clasifica en medicamentos dirigidos y de inmunoterapia, quimioterapia y medicamentos combinados, entre otros. El mercado del cáncer de estómago, según vía de administración, se segmenta en oral, parenteral y otros. En términos de canal de distribución, el mercado del cáncer de estómago se segmenta en farmacias hospitalarias, farmacias minoristas y farmacias en línea. Geográficamente, el mercado del cáncer de estómago está segmentado en América del Norte (Estados Unidos, Canadá y México), Europa (Francia, Alemania, Reino Unido, España, Italia y el resto de Europa), Asia Pacífico (China, India, Japón, Australia, Corea del Sur y el resto de Asia Pacífico), Medio Oriente y África (Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica y el resto de Medio Oriente y África) y América del Sur y Central (Brasil, Argentina y el resto de Asia Pacífico). Resto de América Central y del Sur).
Análisis segmentario:
El mercado del cáncer de estómago, por tipo, se clasifica en adenocarcinomas, tumores del estroma gastrointestinal, tumores neuroendocrinos, linfoma y otros. El segmento de adenocarcinomas tuvo una participación significativa del mercado en 2022 y se espera que registre la CAGR más alta en el mercado del cáncer de estómago durante 2022-2030.
Mercado del cáncer de estómago, por tipo: 2022 y 2030
Según el tratamiento, El mercado del cáncer de estómago se clasifica en medicamentos dirigidos y de inmunoterapia, quimioterapia y medicamentos combinados, entre otros. En 2022, el segmento de quimioterapia y medicamentos combinados tenía una participación significativa del mercado. Se espera que el segmento de medicamentos dirigidos y de inmunoterapia registre la CAGR más alta en el mercado del cáncer de estómago durante 2022-2030. Según la vía de administración, el mercado del cáncer de estómago se segmenta en oral, parenteral y otros. En 2022, el segmento oral tenía una participación significativa del mercado y se prevé que registre la CAGR más rápida durante 2022-2030. Según el canal de distribución, el mercado del cáncer de estómago se clasifica en farmacias hospitalarias, farmacias minoristas y farmacias minoristas. farmacias en línea. El segmento de farmacias hospitalarias tuvo una participación significativa del mercado en 2022 y se espera que registre la CAGR más alta durante 2022-2030.
Análisis regional:
El mercado del cáncer de estómago se divide principalmente en América del Norte, Europa y Asia Pacífico. , América del Sur y Central, y Medio Oriente y África. En 2022, América del Norte captó una parte importante del mercado. En 2022, Estados Unidos tenía la mayor participación del mercado en la región. El crecimiento del mercado en América del Norte se atribuye a la creciente prevalencia del cáncer gástrico, la creciente adopción de terapias dirigidas contra el cáncer y la accesibilidad de tecnología avanzada en los centros de investigación y tratamiento del cáncer. La Sociedad Estadounidense del Cáncer anticipó que en 2023 se diagnosticarán ~26 500 nuevos casos de cáncer gástrico (15 930 en hombres y 10 570 en mujeres). ~11 130 muertes (6690 hombres y 4440 mujeres) se deben al cáncer gástrico. América del Norte está bien desarrollada en términos de accesibilidad a opciones de tratamiento tecnológico avanzado para reducir el cáncer, y las empresas están trabajando arduamente para competir con los actores más conocidos de la región.
Además, las actividades de las empresas en aumento en la realización de ensayos clínicos para el desarrollo de medicamentos eficaces para pacientes con cáncer gástrico y se estima que el aumento de los lanzamientos y aprobaciones de productos impulsará el crecimiento del mercado en la región. En abril de 2021, la Administración de Alimentos y Medicamentos (FDA) aprobó Opdivo de Bristol Myers Squibb, en combinación con fluoropirimidina y quimioterapia que contiene platino, para el tratamiento de pacientes con cáncer gástrico avanzado o metastásico y adenocarcinoma de esófago. Por lo tanto, es probable que dichos factores respalden el crecimiento del mercado en la región durante el período de pronóstico.
Desarrollos de la industria y oportunidades futuras:
A continuación se enumeran numerosas iniciativas adoptadas por actores clave que operan en el mercado mundial del cáncer de estómago:
En enero de 2021, AstraZeneca y Daiichi Sankyo Company recibieron la aprobación de Enhertu de la FDA de EE. UU. para el tratamiento de pacientes adultos con adenocarcinoma gástrico HER2 positivo avanzado o metastásico. Panorama competitivo y empresas clave:
Bristol Myers Squibb Company; Novartis AG; Merck & Co., Inc.; Eli Lilly y compañía; Biocón; Teva Industrias Farmacéuticas Ltd; Celltrion Healthcare Co., Ltd; Samsung Bioepis; Pfizer Inc.; e Ipsen Pharma se encuentran entre los actores destacados en el mercado del cáncer de estómago. Estas empresas se centran en introducir nuevos productos de alta tecnología, avances en productos existentes y expansiones geográficas para satisfacer la creciente demanda de los consumidores en todo el mundo.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Stomach cancer is one of the leading causes of cancer-related deaths and the fifth most common malignancy worldwide. According to Globocan, around 1.1 million new cases of the disease were diagnosed worldwide in 2020. The increase in disease burden and approval of pipeline candidates are anticipated to propel the growth of the market during the forecast period.
Increasing lifestyle changes such as smoking and alcoholism, an increase in obesity, and an increasing prevalence of gastroesophageal reflux disease all act as risk factors for gastric cancer.
The CAGR value of the stomach cancer market during the forecasted period of 2020-2030 is 14.76%
Global stomach cancer market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the stomach cancer market in 2022.
The stomach cancer market majorly consists of the players such include Novartis AG, Pfizer, Inc., Mylan N.V., F. Hoffmann La Roche Ltd., Eli Lilly and Company, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Samsung Bioepis and Bristol Myers Squibb Company.
The adenocarcinomas segment dominated the global stomach cancer market and held the largest market share of 45.34% in 2022.
The List of Companies - Stomach Cancer Market
- Bristol Myers Squibb Company
- Novartis AG
- Merck & Co., Inc.
- Eli Lilly and Company
- Biocon
- Teva Pharmaceutical Industries Ltd.
- Celltrion Healthcare Co., Ltd.
- Samsung Bioepis
- Pfizer Inc.
- Ipsen pharma.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Dec 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Dec 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Dec 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)